| 04/30/2026 3:30 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 10-K/A | |
| 03/26/2026 3:44 PM | Catalyst Pharmaceuticals (1369568) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/18/2026 4:14 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/12/2026 7:03 AM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Daly Richard J (1635393) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Kalb Michael Wayne (1678248) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Del Carmen Jeffrey (1816477) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Daly Richard J (1635393) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer MCENANY PATRICK J (929985) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Harper Molly (1871470) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Miller Steve (1402535) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for CPRX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Sundaram Preethi (1872422) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Tierney David S (1292636) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Elsbernd Brian (1763511) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer DENKHAUS DONALD A (1278439) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Harper Molly (1871470) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:25 PM | Catalyst Pharmaceuticals (1369568) Subject Harper Molly (1871470) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer DENKHAUS DONALD A (1278439) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Sundaram Preethi (1872422) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer MCENANY PATRICK J (929985) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Harper Molly (1871470) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Del Carmen Jeffrey (1816477) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Thompson Tamar (1839248) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Tierney David S (1292636) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Miller Steve (1402535) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Elsbernd Brian (1763511) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/03/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer MCENANY PATRICK J (929985) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/28/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Del Carmen Jeffrey (1816477) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Andrews William T. (1638459) Reporting Catalyst Pharmaceuticals (1369568) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Curran Daniel J. (1887599) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Del Carmen Jeffrey (1816477) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Elsbernd Brian (1763511) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer DENKHAUS DONALD A (1278439) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Daly Richard J (1635393) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Harper Molly (1871470) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer MCENANY PATRICK J (929985) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Tierney David S (1292636) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Kalb Michael Wayne (1678248) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Thompson Tamar (1839248) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Russo Gregg (2058326) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Miller Steve (1402535) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
|
| 11/24/2025 7:08 PM | Catalyst Pharmaceuticals (1369568) Issuer Sundaram Preethi (1872422) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2025 12:23 PM | Catalyst Pharmaceuticals (1369568) Subject Elsbernd Brian (1763511) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 7:17 AM | Catalyst Pharmaceuticals (1369568) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |
| 11/05/2025 3:26 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/01/2025 3:31 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/10/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Elsbernd Brian (1763511) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/05/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Elsbernd Brian (1763511) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/04/2025 10:28 AM | Catalyst Pharmaceuticals (1369568) Subject Elsbernd Brian (1763511) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/03/2025 11:19 AM | Catalyst Pharmaceuticals (1369568) Subject Elsbernd Brian (1763511) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/28/2025 3:30 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K/A | |
| 08/27/2025 3:14 PM | Catalyst Pharmaceuticals (1369568) Subject Tierney David S (1292636) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/26/2025 12:07 PM | Catalyst Pharmaceuticals (1369568) Subject Miller Steve (1402535) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/26/2025 9:46 AM | Catalyst Pharmaceuticals (1369568) Subject Daly Richard J (1635393) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/25/2025 3:30 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/08/2025 4:00 PM | Catalyst Pharmaceuticals (1369568) Issuer Curran Daniel J. (1887599) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 08/04/2025 3:31 PM | Catalyst Pharmaceuticals (1369568) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/06/2025 2:42 PM | Catalyst Pharmaceuticals (1369568) Subject MCENANY PATRICK J (929985) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/02/2025 1:44 PM | Catalyst Pharmaceuticals (1369568) Subject O'Keeffe Charles B (1378656) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/14/2025 9:45 AM | Catalyst Pharmaceuticals (1369568) Subject INGENITO GARY (1279473) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2025 10:14 AM | Catalyst Pharmaceuticals (1369568) Subject INGENITO GARY (1279473) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |